COMBINATION THERAPY WITH CGRP ANTAGONISTS

Disclosed are methods for treating headache, migraine and related symptoms by administering a long acting calcitonin gene related peptide (CGRP) antagonist and a short acting CGRP antagonist. Specifically, the disclosure provides a method for treating, preventing, alleviating, or reducing the frequency of occurrence of headache in a patient in need thereof, comprising administering to the patient: (a) a first calcitonin gene related peptide antagonist (CGRP antagonist) and (b) a second CGRP-antagonist, wherein the first CGRP antagonist is an antibody, and the second CGRP antagonist has a plasma half-life in humans of at most about 60 hours..

Medienart:

Patent

Erscheinungsjahr:

2022

Erschienen:

2022

Enthalten in:

Europäisches Patentamt - (2022) vom: 03. Aug. Zur Gesamtaufnahme - year:2022

Sprache:

Englisch

Beteiligte Personen:

JAKATE ABHIJEET [VerfasserIn]
PERICLOU ANTONIA [VerfasserIn]
BOINPALLY RAMESH [VerfasserIn]

Links:

Volltext [kostenfrei]

Themen:

Sonstige Themen:
615
A61K: Preparations for medical, dental, or toilet purpose (...)
bio
C07K: Peptides (peptides containing β-lactam rings c07d; (...)
C12P: Fermentation or enzyme-using processes to synthesis (...)
che

Anmerkungen:

Source: www.epo.org (no modifications made), First posted: 2022-08-03, Last update posted on www.tib.eu: 2023-09-27, Last updated: 2023-09-29

Patentnummer:

EP4034156

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

EPA002109697